• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.

作者信息

Simoens Steven, Picavet Eline, Dooms Marc, Cassiman David, Morel Thomas

出版信息

Appl Health Econ Health Policy. 2013 Feb;11(1):1-3. doi: 10.1007/s40258-012-0004-y.

DOI:10.1007/s40258-012-0004-y
PMID:23329382
Abstract
摘要

相似文献

1
Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.罕见病药物的成本效益评估：一个科学与政治难题。
Appl Health Econ Health Policy. 2013 Feb;11(1):1-3. doi: 10.1007/s40258-012-0004-y.
2
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.荷兰和苏格兰孤儿药申报监管建议回顾：重点关注潜在的药物经济学评估。
Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006.
3
[Authorization and reimbursement of orphan drugs in an international comparison].[国际比较中罕见病药物的授权与报销]
Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16.
4
Governance of conditional reimbursement practices in The Netherlands.荷兰有条件报销政策的管理
Health Policy. 2015 Feb;119(2):180-5. doi: 10.1016/j.healthpol.2014.10.013. Epub 2014 Nov 1.
5
Orphan drugs and the NHS: consider whom drug regulation is designed to protect.孤儿药与英国国家医疗服务体系：思考药品监管旨在保护谁。
BMJ. 2005 Nov 12;331(7525):1144. doi: 10.1136/bmj.331.7525.1144-b.
6
Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?西欧孤儿药的获取情况：更系统的政策制定真的有助于避免对同一种药物做出不同决策吗？
Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):557-9. doi: 10.1586/14737167.2015.1045882. Epub 2015 May 14.
7
How can the risk that orphan drugs present to budgets be managed better?如何更好地管理罕见病药物给预算带来的风险？
Clin Ther. 2010 Aug;32(9):1640-1. doi: 10.1016/j.clinthera.2010.08.007.
8
[Orphan drugs: drugs for rare diseases].[孤儿药：用于罕见病的药物]
Dtsch Med Wochenschr. 2010 May;135(18):p17.
9
Limits on use of health economic assessments for rare diseases.罕见病卫生经济评估的使用限制。
QJM. 2014 Mar;107(3):241-5. doi: 10.1093/qjmed/hcu016. Epub 2014 Jan 22.
10
Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs.荷兰医生呼吁欧盟评估高成本孤儿药的成本效益。
BMJ. 2012 Aug 13;345:e5461. doi: 10.1136/bmj.e5461.

引用本文的文献

1
GETdb: A comprehensive database for genetic and evolutionary features of drug targets.GETdb：一个关于药物靶点遗传和进化特征的综合数据库。
Comput Struct Biotechnol J. 2024 Apr 3;23:1429-1438. doi: 10.1016/j.csbj.2024.04.006. eCollection 2024 Dec.
2
Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives.基因治疗神经肌肉疾病：健康经济挑战与未来展望。
J Neuromuscul Dis. 2022;9(6):675-688. doi: 10.3233/JND-221540.
3
How to balance valuable innovation with affordable access to medicines in Belgium?
如何在比利时平衡有价值的创新与民众负担得起的药品可及性？
Front Pharmacol. 2022 Sep 16;13:960701. doi: 10.3389/fphar.2022.960701. eCollection 2022.
4
Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?采用传统成本效益分析评估孤儿药的价值：是否合适？
Orphanet J Rare Dis. 2022 Apr 5;17(1):157. doi: 10.1186/s13023-022-02283-z.
5
The Use of Off-Label Medications in Newborn Infants Despite an Approved Alternative Being Available-Results of a National Survey.尽管有已获批的替代药物，新生儿中仍存在超说明书用药的情况——一项全国性调查结果
Pharmacy (Basel). 2022 Jan 25;10(1):19. doi: 10.3390/pharmacy10010019.
6
Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care.在各国需要胰岛素治疗的糖尿病患者中增加胰岛素给药方式的选择及其对未来护理的影响
Front Pharmacol. 2022 Jan 14;12:794363. doi: 10.3389/fphar.2021.794363. eCollection 2021.
7
Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?匈牙利购买一个质量调整生命年（QALY）的花费是否应高于高收入的西欧国家？
Appl Health Econ Health Policy. 2022 May;20(3):291-303. doi: 10.1007/s40258-021-00710-z. Epub 2022 Jan 18.
8
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.研究和开发一种新药需要多少钱？系统评价和评估。
Pharmacoeconomics. 2021 Nov;39(11):1243-1269. doi: 10.1007/s40273-021-01065-y. Epub 2021 Aug 9.
9
A systematic review of moral reasons on orphan drug reimbursement.孤儿药补偿的道德理由系统评价。
Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y.
10
How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.如何评估罕见病药物的价值？欧洲价值评估框架综述。
Front Pharmacol. 2021 May 12;12:631527. doi: 10.3389/fphar.2021.631527. eCollection 2021.